- Home
- AGEN vs EPRX Comparison
AGEN vs EPRX Comparison
Compare AGEN & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- EPRX
- Stock Information
- Founded
- AGEN 1994
- EPRX 2011
- Country
- AGEN United States
- EPRX Canada
- Employees
- AGEN N/A
- EPRX N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- EPRX
- Sector
- AGEN Health Care
- EPRX
- Exchange
- AGEN Nasdaq
- EPRX NYSE
- Market Cap
- AGEN 96.2M
- EPRX 85.5M
- IPO Year
- AGEN 2000
- EPRX N/A
- Fundamental
- Price
- AGEN $2.86
- EPRX $3.37
- Analyst Decision
- AGEN Buy
- EPRX
- Analyst Count
- AGEN 3
- EPRX 0
- Target Price
- AGEN $9.33
- EPRX N/A
- AVG Volume (30 Days)
- AGEN 576.6K
- EPRX 33.3K
- Earning Date
- AGEN 11-12-2024
- EPRX 11-07-2024
- Dividend Yield
- AGEN N/A
- EPRX N/A
- EPS Growth
- AGEN N/A
- EPRX N/A
- EPS
- AGEN N/A
- EPRX N/A
- Revenue
- AGEN $160,427,000.00
- EPRX N/A
- Revenue This Year
- AGEN N/A
- EPRX N/A
- Revenue Next Year
- AGEN $0.04
- EPRX N/A
- P/E Ratio
- AGEN N/A
- EPRX N/A
- Revenue Growth
- AGEN 59.00
- EPRX N/A
- 52 Week Low
- AGEN $2.50
- EPRX $2.20
- 52 Week High
- AGEN $19.69
- EPRX $4.08
- Technical
- Relative Strength Index (RSI)
- AGEN 28.17
- EPRX N/A
- Support Level
- AGEN $2.50
- EPRX N/A
- Resistance Level
- AGEN $2.89
- EPRX N/A
- Average True Range (ATR)
- AGEN 0.29
- EPRX 0.00
- MACD
- AGEN -0.07
- EPRX 0.00
- Stochastic Oscillator
- AGEN 18.75
- EPRX 0.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.